CDT Equity Inc. has entered into an advisory agreement with NJS Foresight Bio‑Advisory, LLC to identify, source and execute out‑licensing deals for assets in its solid‑form patent portfolio. The partnership, announced on January 2 2026, is designed to broaden CDT’s commercial reach and accelerate potential licensing and royalty‑based transactions.
NJS Foresight brings more than 20 years of out‑licensing experience, with principal Dr. Nicholas J. Sarlis reporting over 25 years of clinical and pharmaceutical expertise. The firm has secured numerous agreements across biotechnology and pharmaceuticals, positioning it to support CDT’s strategy of leveraging solid‑form chemistry to extend product life cycles and generate new revenue streams.
Solid‑form patents—such as cocrystals and salts—can provide up to 20 years of protection and improve drug properties like solubility and bioavailability. CDT’s focus on these patents is part of a broader effort to “evergreen” drugs approaching patent cliffs, a strategy that can create long‑term value for both the company and its partners.
CDT’s financials underscore the urgency of monetizing its intellectual property. The company reported a net loss of $7.1 million for the quarter ended September 30 2025 and a nine‑month net loss of $17.9 million. Cash and cash equivalents stood at $3.8 million as of the same date, leaving the company with limited liquidity to fund future development. The out‑licensing partnership is therefore a critical step toward generating cash inflows and improving the balance sheet.
CEO Dr. Andrew Regan said the engagement “continues to assess commercial pathways for our portfolio and sees strong potential for our solid‑form assets to support lifecycle management strategies across the sector.” The comment signals confidence that the partnership will unlock value and provide a more predictable revenue stream, which is essential for a company that has historically avoided late‑stage clinical trials in favor of high‑leverage development strategies.
The partnership is expected to accelerate the conversion of CDT’s solid‑form portfolio into revenue streams while preserving ownership of the underlying data and technology. By leveraging NJS Foresight’s expertise, CDT aims to secure licensing agreements that can generate upfront fees, milestone payments, and ongoing royalties, thereby improving cash flow and reducing reliance on external financing.
The move also aligns with CDT’s broader strategy of using AI and solid‑form chemistry to enhance drug properties and extend patent life. By monetizing its portfolio, the company can reinvest proceeds into new therapeutic candidates, creating a virtuous cycle of innovation and commercialization.
Overall, the partnership represents a material development that could materially alter CDT’s financial trajectory and competitive positioning, making it a significant event for investors and stakeholders.
revised_sentiment_rating
}
importance
medium
high
low
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.